ProPhase Labs, Inc. reported a net revenue of $1.0 million for the three months ended June 30, 2026, a decrease from $1.2 million in the same period last year. For the six months ended June 30, 2026, revenue totaled $2.2 million, down from $2.7 million in the prior year. The decline in revenue is attributed primarily to reduced sales in consumer products, with no revenue generated from diagnostic services in both periods. The company's gross profit for the second quarter was $226,000, reflecting a gross margin of 22.4%, compared to a gross margin of 58.9% in the previous year, indicating significant changes in product mix and cost structure.
Operating expenses for the second quarter decreased to $2.9 million from $4.6 million year-over-year, largely due to reduced personnel and overhead costs. The company reported a net loss from continuing operations of $3.1 million, or $(0.22) per share, an improvement from a loss of $4.5 million, or $(1.08) per share, in the prior year. For the six-month period, the net loss was $8.2 million, or $(0.62) per share, compared to a loss of $9.2 million, or $(2.38) per share, in the same period of 2025.
ProPhase Labs has undergone significant strategic changes, including the deconsolidation of its subsidiary ProPhase Diagnostics, which filed for Chapter 11 bankruptcy in September 2025. This restructuring aims to streamline operations and recover unpaid insurance claims related to COVID-19 testing. The company is also focusing on its genomics and biotechnology segments, with plans to grow its subsidiary Nebula Genomics and the newly formed DNA Complete, which offers whole genome sequencing services.
As of June 30, 2026, ProPhase reported total assets of $57.4 million, down from $59.9 million at the end of 2025. The company’s liabilities increased to $60.5 million, resulting in a stockholders' equity deficit of $3.1 million. The company had cash and cash equivalents of $20,000, a significant decrease from $90,000 at the end of the previous fiscal year. Management has expressed concerns about the company's ability to continue as a going concern, citing liquidity challenges and the need for additional financing to support operations.
Looking ahead, ProPhase Labs is actively pursuing various strategies to improve liquidity, including potential asset monetization, partnerships, and reducing operating expenses. The company remains focused on its core businesses in genomics and biotechnology, with ongoing efforts to commercialize its BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening test and other product candidates. However, the success of these initiatives is contingent on market conditions and the company's ability to execute its plans effectively.
About ProPhase Labs, Inc.
ProPhase Labs is a diversified biotech and genomics company developing and commercializing drugs, dietary supplements, and human genomic testing services. Its core segments include genetic sequencing via Nebula Genomics, drug development through ProPhase BioPharma, and consumer health products under TK Supplements. The company focuses on early disease detection, personalized medicine, and health optimization, serving healthcare providers, consumers, and research institutions worldwide with innovative diagnostics and genomic solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov